Inactive Instrument

Stemline Therapeutics, Inc.

Equities

US85858C1071

Biotechnology & Medical Research

Stemline Therapeutics, Inc. Announces Resignation of Stephen P. Hall as Vice President, Finance and Chief Accounting Officer, Effective from November 30, 2013

November 15, 2013 at 04:45 pm EST

Stemline Therapeutics, Inc. announced that on November 13, 2013, Stephen P. Hall resigned as Vice President, Finance and Chief Accounting Officer of the company. Such resignation will be effective as of November 30, 2013.

Latest news about Stemline Therapeutics, Inc.

Menarini Group Presents Initial Safety and Efficacy Data from Phase 1B/2 Elevate and Electra Combination Studies of Orserdu® (Elacestrant) in Patients with Er+, Her2- Metastatic Breast Cancer At the 2023 San Antonio Breast Cancer Symposium	Dec. 11	CI
Menarini Group and Stemline Therapeutics, Inc. Presents New Progression-Free Survival Data from Emerald Clinical Study of Orserdu (Elacestrant) in Clinically Relevant Subgroups of Patients with Esr1 Mutations At Sabcs 2023	Dec. 08	CI
The Menarini Group and Stemline Therapeutics, Inc. to Present New Data Related to ORSerDU	Nov. 20	CI
Quantum Leap Healthcare Collaborative Initiates Landmark Phase 2 RECAST DCIS Platform Trial to Evaluate Alternative DCIS Treatments with Atossa Therapeutics, Havah Therapeutics, and the Menarini Group	23-10-30	CI
European Commission Approves Menarini Group?s ORSERDU (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation	23-09-20	CI
The Menarini Group and Stemline Therapeutics Announce Results from A New Analysis of the Pivotal EMERALD Clinical Study	23-05-25	CI
Menarini Group Announces New Data on Elacestrant at 2023 ESMO Breast Cancer Congress and 2023 ASCO Annual Meeting	23-05-09	CI
Stemline Therapeutics, Inc. Receives U.S. FDA Approval for ORSERDU	23-01-30	CI
The Menarini Group and Stemline Therapeutics to Present Additional Data from the Phase 3 EMERALD Study of Elacestrant, an Investigational Oral SERD, During the Upcoming San Antonio Breast Cancer Symposium	22-11-30	CI
Menarini Group’s Elacestrant Granted Priority Review by the U.S. FDA for Patients with ER+/HER2- Advanced or Metastatic Breast Cancer	22-08-11	CI
Stemline Therapeutics, Inc. Announces Board Resignations	20-06-10	CI
Stemline Therapeutics, Inc.(NasdaqCM:STML) dropped from S&P Global BMI Index	20-06-10	CI
Stemline Therapeutics, Inc.(NasdaqCM:STML) dropped from S&P TMI Index	20-06-10	CI
Stemline Therapeutics, Inc.(NasdaqCM:STML) dropped from S&P Biotechnology Select Industry Index	20-06-10	CI
Berlin-Chemie AG completed the acquisition of Stemline Therapeutics, Inc..	20-06-09	CI
Stemline Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	20-05-11	CI
Berlin-Chemie AG entered into an agreement to acquire Stemline Therapeutics, Inc. for approximately $610 million.	20-05-03	CI
Transcript : Stemline Therapeutics, Inc., Q4 2019 Earnings Call, Mar 16, 2020	20-03-16
Stemline Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2019	20-03-13	CI
Transcript : Stemline Therapeutics, Inc. Presents at 38th Annual J.P Morgan Healthcare Conference, Jan-15-2020 09:30 AM	20-01-15
Stemline Therapeutics Recaps ELZONRIS Clinical Data Presentations in Patients with Myelofibrosis (Oral Presentation) and Multiple Myeloma at the 61st American Society of Hematology Annual Meeting	19-12-10	CI
Stemline Therapeutics, Inc. Names Robert M. Francomano as Chief Commercial Officer	19-12-06	CI
Transcript : Stemline Therapeutics, Inc., Q3 2019 Earnings Call, Nov 08, 2019	19-11-08
Stemline Therapeutics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-11-07	CI
Certain Common Stock of Stemline Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 7-NOV-2019.	19-11-06	CI

Chart Stemline Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers. SL-401 consists of IL-3 recombinantly fused to a truncated diphtheria toxin payload. SL-701 is an immunotherapy designed to activate the immune system to attack tumors. SL-701 comprises various short synthetic peptides that correspond to epitopes of targets, including IL-13 receptor subunit alpha-2 (IL-13Ra2), ephrin type-A receptor 2 (EphA2) and survivin, present on brain cancer. SL-801 is an oral, small molecule that reversibly inhibits Exportin-1 (XPO1), also known as Chromosome Region Maintenance-1 (CRM-1), a nuclear transport protein.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+8.63%	114B
REGENERON PHARMACEUTICALS, INC.	+13.17%	107B
BIONTECH SE	-12.76%	22.22B
ARGENX SE	-2.45%	21.28B
BEIGENE, LTD.	-7.19%	17.51B
WUXI APPTEC CO., LTD.	-39.93%	17.17B
NEUROCRINE BIOSCIENCES, INC.	+6.67%	14.14B
SAREPTA THERAPEUTICS, INC.	+33.90%	12.2B
LEGEND BIOTECH CORPORATION	-28.60%	7.83B

Bio Therapeutic Drugs